203 related articles for article (PubMed ID: 10652753)
1. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
Zapater P; Horga JF
Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
[TBL] [Abstract][Full Text] [Related]
2. The subject-by-formulation interaction in multivariate bioequivalence.
Cao L; Mathew T
J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
[TBL] [Abstract][Full Text] [Related]
3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
4. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
Leelarasamee A; Rongrungruang Y; Trakulsomboon S; Pongpech P; Thanawattanawanich P; Jithavech P
J Med Assoc Thai; 2008 Jul; 91(7):980-8. PubMed ID: 18839835
[TBL] [Abstract][Full Text] [Related]
6. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
7. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
8. [Bioequivalence studies of pharmaceutical preparations].
Vetchý D; Frýbortová K; Rabisková M; Danecková H
Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
[TBL] [Abstract][Full Text] [Related]
9. Bridging bioequivalence studies.
Liu JP
J Biopharm Stat; 2004 Nov; 14(4):857-67. PubMed ID: 15587968
[TBL] [Abstract][Full Text] [Related]
10. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence review for drug interchangeability.
Chow SC; Shao J
J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
[TBL] [Abstract][Full Text] [Related]
12. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
14. [Bioequivalence and therapeutic exchange of pharmaceutical specialties: application to cyclosporin in renal transplantation].
Pérez Ruixo JJ; Porta B; Jiménez Torres NV
Nefrologia; 2003; 23(1):71-80. PubMed ID: 12708379
[TBL] [Abstract][Full Text] [Related]
15. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
16. A method for the evaluation of individual bioequivalence.
Endrenyi L
Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
[TBL] [Abstract][Full Text] [Related]
18. Novel approach to bioequivalence assessment based on physiologically motivated model.
Tvrdonova M; Chrenova J; Rausova Z; Miklovicova D; Durisova M; Mircioiu C; Dedik L
Int J Pharm; 2009 Oct; 380(1-2):89-95. PubMed ID: 19596057
[TBL] [Abstract][Full Text] [Related]
19. The transitivity of bioequivalence testing: potential for drift.
Anderson S; Hauck WW
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):369-74. PubMed ID: 8880284
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
